STOCK TITAN

Amphastar CFO exercises options, sells 11,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Amphastar Pharmaceuticals, Inc. (AMPH) CFO, EVP & Treasurer William J. Peters exercised 11,000 options at $17.99 per share on November 16, 2026, acquiring 11,000 common shares, then sold 11,000 shares at $29.99 per share that day. The sale was made under a Rule 10b5-1 trading plan adopted March 10, 2026. The options were fully vested and immediately exercisable; 56,833 options were reported following the exercise.

Insider PETERS WILLIAM J
Role CFO, EVP & TREASURER
Sold 11,000 shs ($330K)
Approx. gross sale proceeds $330K
Approx. exercise cost $198K
Approx. pre-tax spread $132K
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F2 11,000 $0.00 $0.00
Exercise Common Stock 11,000 $17.99 $198K
Sale Common Stock F1 11,000 $29.99 $330K
Holdings After Transaction: Employee Stock Option (right to buy) — 56,833 options (Direct); Common Stock — 167,076 shares (Direct)
Footnotes (2)
  1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2026.
  2. F2. Shares subject to the option are fully vested and immediately exercisable.
Options exercised 11,000 options November 16, 2026
Exercise price $17.99 per share Options exercised November 16, 2026
Common shares acquired 11,000 shares Upon option exercise on November 16, 2026
Common shares sold 11,000 shares November 16, 2026
Sale price $29.99 per share Sale on November 16, 2026
Options following exercise 56,833 options Reported following the November 16, 2026 exercise
Rule 10b5-1 trading plan regulatory
"the sale was made under a Rule 10b5-1 trading plan adopted March 10, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
fully vested and immediately exercisable technical
"Shares subject to the option are fully vested and immediately exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AMPH shares did William J. Peters sell, and at what price?

William J. Peters sold 11,000 shares at $29.99 per share on November 16, 2026. The sale was made under a Rule 10b5-1 trading plan adopted March 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PETERS WILLIAM J

(Last)(First)(Middle)
C/O AMPHASTAR PHARMACEUTICALS, INC.
11570 6TH STREET

(Street)
RANCHO CUCAMONGA CALIFORNIA 91730

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Amphastar Pharmaceuticals, Inc. [ AMPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CFO, EVP & TREASURER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M11,000A$17.99178,076D
Common Stock11/16/2026S(1)11,000D$29.99167,076D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$17.9911/16/2026M11,000 (2)03/17/2031Common Stock11,000$056,833D
Explanation of Responses:
1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2026.
2. Shares subject to the option are fully vested and immediately exercisable.
/s/ William J. Peters11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading